Celcuity (CELC) Stock Overview
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CELC Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeCelcuity Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$130.71 |
| 52 Week High | US$151.02 |
| 52 Week Low | US$9.51 |
| Beta | 0.093 |
| 1 Month Change | 13.11% |
| 3 Month Change | 22.45% |
| 1 Year Change | 1,141.31% |
| 3 Year Change | 1,243.37% |
| 5 Year Change | 402.92% |
| Change since IPO | 814.70% |
Recent News & Updates
Recent updates
Priority FDA Review And Phase III Data Will Transform This Oncology Pure Play
Catalysts About Celcuity Celcuity is a clinical stage oncology company focused on developing gedatolisib, a targeted therapy for advanced breast and prostate cancers. What are the underlying business or industry changes driving this perspective?
Single Drug Dependence And Heavy Financing Will Shape A Challenging Future
Catalysts About Celcuity Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer. What are the underlying business or industry changes driving this perspective?
Future Oncology Approvals And Pipeline Expansion Will Support A Stable Long Term Outlook
Catalysts About Celcuity Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer. What are the underlying business or industry changes driving this perspective?Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond
Summary Celcuity Inc. surged over 750% in 2025 on best-in-class Phase 3 data for gedatolisib in HR+/HER2- advanced breast cancer. GEDATOLISIB demonstrated superior efficacy and safety versus standards of care, with median PFS of 9.3 months in VIKTORIA-1 and favorable adverse event profile. Management projects peak revenues of $2.5–$3 billion for gedatolisib; current cash position is nearly $500 million, supporting regulatory and commercial milestones. I maintain a long-term Buy rating on CELC, anticipating further upside as pivotal data, regulatory filings, and potential M&A activity unfold through 2027–2028. Read the full article on Seeking AlphaCelcuity: Breast Cancer Drug Developer With Upcoming Catalysts
Summary Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 trials. Gedatolisib shows promising efficacy and safety, especially in combination therapies for advanced breast cancer, with significant ORR and mPFS improvements. Financially, Celcuity has a strong cash position and secured funding, ensuring a runway through 2026, despite patent expiration risks. Despite Stifel's buy rating and blockbuster potential, the risk-reward profile of CELC remains unattractive at this stage. Read the full article on Seeking AlphaCelcuity: Flying A Phase 3 Trial Right Under Your Nose
Summary Celcuity Inc. is a cancer-focused biotech company with one pipeline candidate, gedatolisib, showing promise in breast and prostate cancer. Gedatolisib is a differentiated PI3K inhibitor with a favorable tolerability profile, but faces risks associated with the history of PI3K inhibition in cancer medicine. CELC has a strong cash position to fund key data-related catalysts, but the jump from phase 1 to phase 3 trials carries inherent risks. Read the full article on Seeking AlphaCelcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment
Shares of micro-cap company Celcuity (NASDAQ:CELC) added 12.7% to $10.42 after hours on Monday as the clinical stage biotech was granted a Breakthrough Therapy designation by the U.S. FDA for its breast cancer treatment gedatolisib. The U.S. drug regulator granted gedatolisib the designation for the treatment of patients with HR+/HER2- metastatic breast cancer whose disease progressed during treatment with a CDK4/6 therapy and a non-steroidal aromatase inhibitor. The FDA's Breakthrough Therapy designation process is meant to expedite the review of drugs that are intended for the treatment of serious diseases. CELC's gedatolisib had previously received a FDA Fast Track designation in Jan.Celcuity: Nipping The Oncogenic Bud
Celcuity analyzes live tumor cells for oncogenic pathways. It identifies abnormal oncogenic signaling pathways to detect new treatment options. The company develops targeted therapies for cancer patients.Shareholder Returns
| CELC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.7% | 1.2% | 2.1% |
| 1Y | 1,141.3% | 41.9% | 30.6% |
Return vs Industry: CELC exceeded the US Biotechs industry which returned 41.9% over the past year.
Return vs Market: CELC exceeded the US Market which returned 31% over the past year.
Price Volatility
| CELC volatility | |
|---|---|
| CELC Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CELC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CELC's weekly volatility has decreased from 25% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 155 | Brian Sullivan | www.celcuity.com |
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib.
Celcuity Inc. Fundamentals Summary
| CELC fundamental statistics | |
|---|---|
| Market cap | US$6.74b |
| Earnings (TTM) | -US$177.04m |
| Revenue (TTM) | n/a |
Is CELC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CELC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$177.04m |
| Earnings | -US$177.04m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 14, 2026
| Earnings per share (EPS) | -3.66 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 320.1% |
How did CELC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 09:17 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celcuity Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arlinda Lee | Canaccord Genuity |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Alexander Nowak | Craig-Hallum Capital Group LLC |